Therapy and clinical trials

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 281-282

  Sodhi, Nishtha ^a   Krasuski, Richard A ^b  

^a Department of Internal Medicine ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 145; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; NIACIN; OLIGONUCLEOTIDES; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84880090046     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283616351     Document Type: Editorial

References (12)

1. Jones PH, Nair R, Thakker KM. Coronary Heart Disease: Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012; 1:e001800; doi:10.1161/JAHA.112.001800.
2. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34:216-219.
3. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. http://www.thrivestudy.org. [Accessed 1 March 2013].
4. The AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
5. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
6. The ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
7. ACCELERATE: Assessment of Clinical effects of CholestEryL Ester transfeR protein inhibition with evAcetrapib in patienTs at a high-risk for vascular outcomEs. 2012. ClinicalTrials.gov Identifier: NCT01687998. ClinicalTrials.gov.
8. REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. 2010. ClinicalTrials.gov Identifier: NCT01252953. Clinical-Trials.gov.
9. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomized controlled trial. Lancet 2012; 380:29-36.
10. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effectsofAMG 145, amonoclonal antibodytoproprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417.
11. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a ran domized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-2292.
12. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant Patients: The goal achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects (GAUSS). JAMA 2012; 308:2497-2506.